Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents
Abstract The incidence of cardiovascular disorders is one of the most concerns among people who underwent cancer therapy. The heart side effects of cancer therapy may occur during treatment to some years after the end of treatment. Some epidemiological studies confirm that heart diseases are one of the most common reasons for mortality among patients that were received treatment for cancer. Experimental studies and also clinical investigations indicate that inflammatory changes such as pericarditis, myocarditis, and also fibrosis are key mechanisms of cardiac diseases following chemotherapy/radiotherapy. It seems that chronic oxidative stress, massive cell death, and chronic overproduction of pro-inflammatory and pro-fibrosis cytokines are the key mechanisms of cardiovascular diseases following cancer therapy. Furthermore, infiltration of inflammatory cells and upregulation of some enzymes such as NADPH Oxidases are a hallmark of heart diseases after cancer therapy. In the current review, we aim to explain how radiation or chemotherapy can induce inflammatory and fibrosis-related diseases in the heart. We will explain the cellular and molecular mechanisms of cardiac inflammation and fibrosis following chemo/radiation therapy, and then review some adjuvants to reduce the risk of inflammation and fibrosis in the heart..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Inflammopharmacology - 30(2021), 1 vom: 23. Nov., Seite 73-89 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Run [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Cardiovascular diseases |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 |
|---|
| doi: |
10.1007/s10787-021-00894-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078229970 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078229970 | ||
| 003 | DE-627 | ||
| 005 | 20230511071630.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10787-021-00894-9 |2 doi | |
| 035 | |a (DE-627)OLC2078229970 | ||
| 035 | |a (DE-He213)s10787-021-00894-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Yang, Run |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiac inflammation and fibrosis following chemo/radiation therapy: mechanisms and therapeutic agents |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021 | ||
| 520 | |a Abstract The incidence of cardiovascular disorders is one of the most concerns among people who underwent cancer therapy. The heart side effects of cancer therapy may occur during treatment to some years after the end of treatment. Some epidemiological studies confirm that heart diseases are one of the most common reasons for mortality among patients that were received treatment for cancer. Experimental studies and also clinical investigations indicate that inflammatory changes such as pericarditis, myocarditis, and also fibrosis are key mechanisms of cardiac diseases following chemotherapy/radiotherapy. It seems that chronic oxidative stress, massive cell death, and chronic overproduction of pro-inflammatory and pro-fibrosis cytokines are the key mechanisms of cardiovascular diseases following cancer therapy. Furthermore, infiltration of inflammatory cells and upregulation of some enzymes such as NADPH Oxidases are a hallmark of heart diseases after cancer therapy. In the current review, we aim to explain how radiation or chemotherapy can induce inflammatory and fibrosis-related diseases in the heart. We will explain the cellular and molecular mechanisms of cardiac inflammation and fibrosis following chemo/radiation therapy, and then review some adjuvants to reduce the risk of inflammation and fibrosis in the heart. | ||
| 650 | 4 | |a Heart | |
| 650 | 4 | |a Cardiovascular diseases | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Doxorubicin | |
| 700 | 1 | |a Tan, Changming |4 aut | |
| 700 | 1 | |a Najafi, Masoud |0 (orcid)0000-0002-6341-9007 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Inflammopharmacology |d Springer International Publishing, 1991 |g 30(2021), 1 vom: 23. Nov., Seite 73-89 |w (DE-627)170602893 |w (DE-600)1080058-X |w (DE-576)505034115 |x 0925-4692 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2021 |g number:1 |g day:23 |g month:11 |g pages:73-89 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10787-021-00894-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 30 |j 2021 |e 1 |b 23 |c 11 |h 73-89 | ||